Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + gemcitabine with gabapentin or pregabalin in advanced pancreatic cancer
ChiCTR2500112959Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, gemcitabine, gabapentin and pregabalin in pancreatic cancer (PC), sponsored by Second Hospital of Lanzhou University. Primary endpoint: 1-year overall survival rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
paclitaxelgemcitabinegabapentinpregabalin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500112959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112959.